39. 中毒性表皮壊死症 Toxic epidermal necrolysis Clinical trials / Disease details

臨床試験数 : 13 / 薬物数 : 19 - (DrugBank : 8) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 103

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02126020 (ClinicalTrials.gov)	November 2014	27/4/2014	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid	Drug: topical infliximab	James Chodosh, MD, MPH	Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal ...	Withdrawn	18 Years	80 Years	All	0	Phase 1/Phase 2	United States;Canada
2	NCT01256489 (ClinicalTrials.gov)	December 2010	19/11/2010	Infliximabto Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Synd ...	InfliximabTherapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens John ...	Stevens-Johnson Syndrome;Corneal Blindness	Drug: Infliximab	Massachusetts Eye and Ear Infirmary	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 1/Phase 2	United States
3	NCT00372723 (ClinicalTrials.gov)	July 2006	5/9/2006	Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)	Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Ne ...	Toxic Epidermal Necrolysis	Drug: Remicaide (infliximab)	Loyola University	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 2	United States

First Previous1Next Last